Search

Your search keyword '"Iannone, Florenzo' showing total 2,051 results
Start Over Author "Iannone, Florenzo
2,051 results on '"Iannone, Florenzo'

1. Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study

Author

Bente Glintborg, Merete Lund Hetland, Tore K Kvien, Brigitte Michelsen, Florenzo Iannone, Karel Pavelka, Ziga Rotar, Maria Jose Santos, Catalin Codreanu, Anne Gitte Loft, Maria Sole Chimenti, Gary J Macfarlane, Gareth T Jones, Mikkel Østergaard, Jakub Zavada, Bjorn Gudbjornsson, Gerður Gröndal, Lykke Midtbøll Ørnbjerg, Adrian Ciurea, Daniela Di Giuseppe, Michael J Nissen, Anabela Barcelos, Irene van der Horst-Bruinsma, Sara Nysom Christiansen, Isabel Castrejón, Sella Aarrestad Provan, Heikki Relas, Simon Horskjær Rasmussen, Ismail Sari, Anna-Mari Hokkanen, Johan K Wallman, Sigrid Vorobjov, Marion Pons, Marleen van de Sande, Corina Mogosan, Lucia Otero-Varela, Karin Laas, Yesim Erez, and Katja Perdan Pirkmajer

Subjects
Medicine
Abstract

Objectives To compare the treatment effectiveness of secukinumab in radiographic (r) versus non-radiographic (nr) axial spondyloarthritis (axSpA) patients treated in routine care across Europe.Methods Prospectively collected data on secukinumab-treated axSpA patients with known radiographic status were pooled from nine countries.Remission rates based on patient-reported outcomes (PROs; Numeric Rating Scale (0–10), for example, pain ≤2/Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ≤2 and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (ID)

Published
2024
Full Text
View/download PDF

2. Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry

Author

Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca

Published
2024
Full Text
View/download PDF

3. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

Author

Distler, Oliver, Becker, Mike, De Decker, Melissa, Fegatelli, Danilo Alunni, Siegert, Elise, Castellví, Ivan, Cauli, Alberto, Solanki, Kamal, Dagna, Lorenzo, Martin, Mickaël, Moroncini, Gianluca, Poormoghim, Hadi, Kuwana, Masataka, Carreira, Patricia E., Airò, Paolo, Bergmann, Christina, Spierings, Julia, Tanaka, Yoshiya, Selvi, Enrico, Soukup, Tomas, Colalillo, Amalia, Hachulla, Eric, Pellicano, Chiara, Smith, Vanessa, Riemekasten, Gabriela, Zanatta, Elisabetta, Henes, Jörg, Launay, David, Marcoccia, Antonella, Gheorghiu, Ana Maria, Truchetet, Marie-Elise, Iannone, Florenzo, Simeón Aznar, Carmen Pilar, Oliveira, Susana, Vonk, Madelon, Del Galdo, Francesco, and Rosato, Edoardo

Published
2024
Full Text
View/download PDF

4. Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry

Author

Triggianese, Paola, Vitale, Antonio, Lopalco, Giuseppe, Mayrink Giardini, Henrique Ayres, Ciccia, Francesco, Al-Maghlouth, Ibrahim, Ruscitti, Piero, Sfikakis, Petros Paul, Iannone, Florenzo, de Brito Antonelli, Isabele Parente, Patrone, Martina, Asfina, Kazi Nur, Di Cola, Ilenia, Laskari, Katerina, Gaggiano, Carla, Tufan, Abdurrahman, Sfriso, Paolo, Dagna, Lorenzo, Giacomelli, Roberto, Hinojosa-Azaola, Andrea, Ragab, Gaafar, Fotis, Lampros, Direskeneli, Haner, Spedicato, Veronica, Dagostin, Marilia Ambiel, Iacono, Daniela, Ali, Hebatallah Hamed, Cipriani, Paola, Sota, Jurgen, Kardas, Riza Can, Bindoli, Sara, Campochiaro, Corrado, Navarini, Luca, Gentileschi, Stefano, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Saad, Moustafa Ali, Kourtesi, Katerina, Alibaz-Oner, Fatma, Sevik, Gizem, Iagnocco, Annamaria, Makowska, Joanna, Govoni, Marcello, Monti, Sara, Maggio, Maria Cristina, La Torre, Francesco, Del Giudice, Emanuela, Hernández-Rodríguez, José, Bartoloni, Elena, Emmi, Giacomo, Chimenti, Maria Sole, Maier, Armin, Simonini, Gabriele, Conti, Giovanni, Olivieri, Alma Nunzia, Tarsia, Maria, De Paulis, Amato, Lo Gullo, Alberto, Więsik-Szewczyk, Ewa, Viapiana, Ombretta, Ogunjimi, Benson, Tharwat, Samar, Erten, Sukran, Nuzzolese, Rossana, Karamanakos, Anastasios, Frassi, Micol, Conforti, Alessandro, Caggiano, Valeria, Marino, Achille, Sebastiani, Gian Domenico, Gidaro, Antonio, Tombetti, Enrico, Carubbi, Francesco, Rubegni, Giovanni, Cartocci, Alessandra, Balistreri, Alberto, Fabiani, Claudia, Frediani, Bruno, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

5. Unfolding dermatologic spectrum of Behçet’s disease in Italy: real-life data from the International AIDA Network Behçet’s disease Registry

Author

D’Onghia, Martina, Cinotti, Elisa, Cartocci, Alessandra, Vitale, Antonio, Caggiano, Valeria, Tognetti, Linda, La Marca, Francesca, Sota, Jurgen, Gentileschi, Stefano, Rubegni, Giovanni, Lopalco, Giuseppe, Guerriero, Silvana, Govoni, Marcello, Monti, Sara, Ruscitti, Piero, Angeli, Fabrizio, Carubbi, Francesco, Giacomelli, Roberto, Ciccia, Francesco, Piga, Matteo, Emmi, Giacomo, Costi, Stefania, Sebastiani, Gian Domenico, Iannone, Florenzo, Spedicato, Veronica, Alessio, Giovanni, Ruffilli, Francesca, Milanesi, Alessandra, Gentile, Martina, Crisafulli, Francesca, Alunno, Alessia, Navarini, Luca, Iacono, Daniela, Cauli, Alberto, Ricci, Francesca, Gaggiano, Carla, Tarsia, Maria, Bartoloni, Elena, Conti, Giovanni, Viapiana, Ombretta, Gobbi, Francesca Li, de Paulis, Amato, Parronchi, Paola, Del Giudice, Emanuela, Barone, Patrizia, Olivieri, Alma Nunzia, Bizzi, Emanuele, Maggio, Maria Cristina, Balistreri, Alberto, Frediani, Bruno, Tosi, Gian Marco, Fabiani, Claudia, Rubegni, Pietro, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

7. Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis – relationship with the reason for withdrawal from the previous treatment

Author

Ørnbjerg, Lykke Midtbøll, Brahe, Cecilie Heegaard, Linde, Louise, Jacobsson, Lennart, Nissen, Michael J., Kristianslund, Eirik Klami, Santos, Maria José, Nordström, Dan, Rotar, Ziga, Gudbjornsson, Bjorn, Onen, Fatos, Codreanu, Catalin, Lindström, Ulf, Möller, Burkhard, Kvien, Tore K., Barcelos, Anabela, Eklund, Kari K., Tomšič, Matija, Love, Thorvardur Jon, Can, Gercek, Ionescu, Ruxandra, Loft, Anne Gitte, Mann, Herman, Pavelka, Karel, van de Sande, Marleen, van der Horst-Bruinsma, I.E., Suarez, Manuel Pombo, Sánchez-Piedra, Carlos, Macfarlane, Gary J., Iannone, Florenzo, Michelsen, Brigitte, Hyldstrup, Lise Hejl, Krogh, Niels Steen, Østergaard, Mikkel, and Hetland, Merete Lund

Published
2024
Full Text
View/download PDF

8. Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

Author

Vitale, Antonio, Caggiano, Valeria, Martin-Nares, Eduardo, Frassi, Micol, Dagna, Lorenzo, Hissaria, Pravin, Sfriso, Paolo, Hernández-Rodríguez, José, Ruiz-Irastorza, Guillermo, Monti, Sara, Tufan, Abdurrahman, Piga, Matteo, Giardini, Henrique A Mayrink, Lopalco, Giuseppe, Viapiana, Ombretta, De Paulis, Amato, Triggianese, Paola, Vitetta, Rosetta, de-la-Torre, Alejandra, Fonollosa, Alex, Caroni, Federico, Sota, Jurgen, Conticini, Edoardo, Sbalchiero, Jessica, Renieri, Alessandra, Casamassima, Giulia, Wiesik-Szewczyk, Ewa, Yildirim, Derya, Hinojosa-Azaola, Andrea, Crisafulli, Francesca, Franceschini, Franco, Campochiaro, Corrado, Tomelleri, Alessandro, Callisto, Alicia, Beecher, Mark, Bindoli, Sara, Baggio, Chiara, Gómez-Caverzaschi, Verónica, Pelegrín, Laura, Soto-Peleteiro, Adriana, Milanesi, Alessandra, Vasi, Ibrahim, Cauli, Alberto, Antonelli, Isabele Parente de Brito, Iannone, Florenzo, Bixio, Riccardo, Casa, Francesca Della, Mormile, Ilaria, Gurnari, Carmelo, Fiorenza, Alessia, Mejia-Salgado, Germán, Kawakami-Campos, Perla Ayumi, Ragab, Gaafar, Ciccia, Francesco, Ruscitti, Piero, Bocchia, Monica, Balistreri, Alberto, Tosi, Gian Marco, Frediani, Bruno, Cantarini, Luca, and Fabiani, Claudia

Published
2024
Full Text
View/download PDF

9. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

Author

Linde, Louise, Ørnbjerg, Lykke M., Rasmussen, Simon H., Love, Thorvardur Jon, Loft, Anne Gitte, Závada, Jakub, Vencovský, Jiří, Laas, Karin, Nordstrom, Dan, Sokka-Isler, Tuulikki, Gudbjornsson, Bjorn, Gröndal, Gerdur, Iannone, Florenzo, Ramonda, Roberta, Hellamand, Pasoon, Kristianslund, Eirik K., Kvien, Tore K., Rodrigues, Ana M., Santos, Maria J., Codreanu, Catalin, Rotar, Ziga, Tomšič, Matija, Castrejon, Isabel, Díaz-Gonzáles, Federico, Di Giuseppe, Daniela, Ljung, Lotta, Nissen, Michael J., Ciurea, Adrian, Macfarlane, Gary J., Heddle, Maureen, Glintborg, Bente, Østergaard, Mikkel, and Hetland, Merete L.

Published
2023
Full Text
View/download PDF

10. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries

Author

Dominique, Alyssa, Hetland, Merete Lund, Finckh, Axel, Gottenberg, Jacques-Eric, Iannone, Florenzo, Caporali, Roberto, Kou, Tzuyung Douglas, Nordstrom, Dan, Hernandez, Maria Victoria, Sánchez-Piedra, Carlos, Sánchez-Alonso, Fernando, Pavelka, Karel, Bond, T. Christopher, and Simon, Teresa A.

Published
2023
Full Text
View/download PDF

11. Large language model-driven sentiment analysis for facilitating fibromyalgia diagnosis

Author

Florenzo Iannone and Vincenzo Venerito

Subjects
Medicine
Abstract

Background Fibromyalgia (FM) is a complex disorder with widespread pain and emotional distress, posing diagnostic challenges. FM patients show altered cognitive and emotional processing, with a preferential allocation of attention to pain-related information. This attentional bias towards pain cues can impair cognitive functions such as inhibitory control, affecting patients’ ability to manage and express emotions. Sentiment analysis using large language models (LLMs) can provide insights by detecting nuances in pain expression. This study investigated whether open-source LLM-driven sentiment analysis could aid FM diagnosis.Methods 40 patients with FM, according to the 2016 American College of Rheumatology Criteria and 40 non-FM chronic pain controls referred to rheumatology clinics, were enrolled. Transcribed responses to questions on pain and sleep were machine translated to English and analysed by the LLM Mistral-7B-Instruct-v0.2 using prompt engineering targeting FM-associated language nuances for pain expression (‘prompt-engineered’) or an approach without this targeting (‘ablated’). Accuracy, precision, recall, specificity and area under the receiver operating characteristic curve (AUROC) were calculated using rheumatologist diagnosis as ground truth.Results The prompt-engineered approach demonstrated accuracy of 0.87, precision of 0.92, recall of 0.84, specificity of 0.82 and AUROC of 0.86 for distinguishing FM. In comparison, the ablated approach had an accuracy of 0.76, precision of 0.75, recall of 0.77, specificity of 0.75 and AUROC of 0.76. The accuracy was superior to the ablated approach (McNemar’s test p

Published
2024
Full Text
View/download PDF

12. Management of pregnancy in autoimmune rheumatic diseases: maternal disease course, gestational and neonatal outcomes and use of medications in the prospectiveItalian P-RHEUM.it study

Author

Carlo Alberto Scirè, Alessandra Bortoluzzi, Andrea Doria, Micaela Fredi, Marcello Govoni, Chiara Tani, Angela Tincani, Maurizio Cutolo, Marta Mosca, Florenzo Iannone, Elena Elefante, Margherita Zen, Maddalena Larosa, Paola Conigliaro, Maria Sole Chimenti, Veronica Codullo, Cecilia Nalli, Veronique Ramoni, Carlomaurizio Montecucco, Marco Taglietti, Valentina Picerno, Greta Carrara, Laura Andreoli, Chiara Marvisi, Carlo Salvarani, Serena Guiducci, Antonio Luca Brucato, Franco Franceschini, Giandomenico Sebastiani, Marta Tonello, Silvia Bellando-Randone, Dina Zucchi, Giovanna Cuomo, Maria Letizia Urban, Maria Gerosa, Ettore Silvagni, Elisa Bellis, Francesca Bellisai, Alessandra Milanesi, Patrizia Rovere-Querini, Ariela Hoxha, Salvatore D'Angelo, Sonia Zatti, Emanuele Bizzi, Gianpiero Landolfi, Bernd Raffeiner, Leonardo Santo, Teresa Del Ross, Maria Stefania Cutro, Giulia Pazzola, Oscar Massimiliano Epis, Sara Benedetti, Maria Favaro, Antonia Calligaro, Annamaria Iuliano, Sabrina Gori, Francesca Crisafulli, Matteo Filippini, Maria Chiara Gerardi, Maria Grazia Lazzaroni, Cecilia Beatrice Chighizola, Laura Trespidi, Maria Chiara Ditto, Cristina Zanardini, Roberta Erra, Melissa Padovan, Irene Mattioli, Davide Rozza, Claudia Lomater, Daniele Lini, Valentina Canti, Rebecca De Lorenzo, Francesca Ruffilli, Giulia Carrea, Ludovica Cavallo, Alessandra Zambon, Claudia Barison, Francesca Serale, Paolo Semeraro, Chiara Loardi, Rossana Orabona, Francesca Ramazzotto, Giulia Fontana, Giorgia Gozzoli, Paola Bizioli, Roberto Felice Caporali, Manuela Wally Ossola, Beatrice Maranini, Danila Morano, Rosita Verteramo, Maria Grazia Anelli, Marlea Lavista, Anna Abbruzzese, Carlo Giuseppe Fasano, Teresa Carbone, Angela Anna Padula, Giuseppina Comitini, Giuseppina Di Raimondo, Clizia Gagliardi, Gloria Crepaldi, Estrella Garcia Gonzalez, Anna Paola Pata, Martina Zerbinati, and Sara Tonetta

Subjects
Medicine
Abstract

Objectives To investigate pregnancy outcomes in women with autoimmune rheumatic diseases (ARD) in the Italian prospective cohort study P-RHEUM.it.Methods Pregnant women with different ARD were enrolled for up to 20 gestational weeks in 29 Rheumatology Centres for 5 years (2018–2023). Maternal and infant information were collected in a web-based database.Results We analysed 866 pregnancies in 851 patients (systemic lupus erythematosus was the most represented disease, 19.6%). Maternal disease flares were observed in 135 (15.6%) pregnancies. 53 (6.1%) pregnancies were induced by assisted reproduction techniques, 61 (7%) ended in miscarriage and 11 (1.3%) underwent elective termination. Obstetrical complications occurred in 261 (30.1%) pregnancies, including 2.3% pre-eclampsia. Two cases of congenital heart block were observed out of 157 pregnancies (1.3%) with anti-Ro/SSA. Regarding treatments, 244 (28.2%) pregnancies were treated with glucocorticoids, 388 (44.8%) with hydroxychloroquine, 85 (9.8%) with conventional synthetic disease-modifying anti-rheumatic drugs and 122 (14.1%) with biological disease-modifying anti-rheumatic drugs. Live births were 794 (91.7%), mostly at term (84.9%); four perinatal deaths (0.5%) occurred. Among 790 newborns, 31 (3.9%) were small-for-gestational-age and 169 (21.4%) had perinatal complications. Exclusive maternal breast feeding was received by 404 (46.7%) neonates. The Edinburgh Postnatal Depression Scale was compiled by 414 women (52.4%); 89 (21.5%) scored positive for emotional distress.Conclusions Multiple factors including preconception counselling and treat-to-target with pregnancy-compatible medications may have contributed to mitigate disease-related risk factors, yielding limited disease flares, good pregnancy outcomes and frequency of complications which were similar to the Italian general obstetric population. Disease-specific issues need to be further addressed to plan preventative measures.

Published
2024
Full Text
View/download PDF

13. Retention rate of biologic and targeted synthetic anti-rheumatic drugs in elderly rheumatoid arthritis patients: data from GISEA registry

Author

Andreina Manfredi, Marco Fornaro, Chiara Bazzani, Simone Perniola, Alberto Cauli, Alessandra Rai, Ennio Giulio Favalli, Serena Bugatti, Maurizio Rossini, Rosario Foti, Fabrizio Conti, Giuseppe Lopalco, Anna Scalvini, Cristina Garufi, Mattia Congia, Roberto Gorla, Elisa Gremese, Fabiola Atzeni, Roberto Caporali, Florenzo Iannone, and Marco Sebastiani

Subjects
rheumatoid arthritis, elderly, comorbidities, treatment, retention rate, safety, Medicine (General), R5-920
Abstract

ObjectivesAn increased number of elderly individuals affected by rheumatoid arthritis (RA) has been reported, including both patients with RA onset in advanced age and patients aged with the disease. In this registry-based study, we aimed to analyze the retention rate and cause of discontinuation of biologic (b) and targeted synthetic (ts)-disease-modifying anti-rheumatic drugs (DMARDs) in RA patients over 65 year old.MethodsRA patients enrolled in the Italian GISEA registry and starting a b- or a ts-DMARD over 65 years of age were included. Demographic, clinical, serologic, and therapeutic features were collected.ResultsA total of 1,221 elderly RA patients were analyzed (mean age 71.6 ± 5.2 years). RA was diagnosed before 65 years in 72.5% of cases, a 60.6% of patients experienced a previous b- or ts-DMARD. In patients older than 65 initiating a new b- or ts-DMARDS, tumor necrosis factor alpha inhibitors (TNFi) were prescribed in 29.6% of patients, abatacept in 24.8%, anti-interleukin 6 receptor antagonists (anti-IL6R) in 16.3%, Janus kinases inhibitors (JAKi) in 24.9%, and rituximab in 4.4%. The main causes of discontinuation were primary or secondary inadequate responses (66.1%). The median retention rate for all treatments was 181.3 weeks. A statistically higher retention rate was observed for abatacept when compared to TNFi (p = 0.02), JAKi (p

Published
2024
Full Text
View/download PDF

14. Commonalities and differences in set-up and data collection across European spondyloarthritis registries — results from the EuroSpA collaboration

Author

Louise Linde, Lykke M. Ørnbjerg, Simon H. Rasmussen, Thorvardur Jon Love, Anne Gitte Loft, Jakub Závada, Jiří Vencovský, Karin Laas, Dan Nordstrom, Tuulikki Sokka-Isler, Bjorn Gudbjornsson, Gerdur Gröndal, Florenzo Iannone, Roberta Ramonda, Pasoon Hellamand, Eirik K. Kristianslund, Tore K. Kvien, Ana M. Rodrigues, Maria J. Santos, Catalin Codreanu, Ziga Rotar, Matija Tomšič, Isabel Castrejon, Federico Díaz-Gonzáles, Daniela Di Giuseppe, Lotta Ljung, Michael J. Nissen, Adrian Ciurea, Gary J. Macfarlane, Maureen Heddle, Bente Glintborg, Mikkel Østergaard, and Merete L. Hetland

Subjects
Spondyloarthritis, European registries, Clinical data collection, Collaborative research, Real-world evidence, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background In European axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) clinical registries, we aimed to investigate commonalities and differences in (1) set-up, clinical data collection; (2) data availability and completeness; and (3) wording, recall period, and scale used for selected patient-reported outcome measures (PROMs). Methods Data was obtained as part of the EuroSpA Research Collaboration Network and consisted of (1) an online survey and follow-up interview, (2) upload of real-world data, and (3) selected PROMs included in the online survey. Results Fifteen registries participated, contributing 33,948 patients (axSpA: 21,330 (63%), PsA: 12,618 (37%)). The reported coverage of eligible patients ranged from 0.5 to 100%. Information on age, sex, biological/targeted synthetic disease-modifying anti-rheumatic drug treatment, disease duration, and C-reactive protein was available in all registries with data completeness between 85% and 100%. All PROMs (Bath Ankylosing Spondylitis Disease Activity and Functional Indices, Health Assessment Questionnaire, and patient global, pain and fatigue assessments) were more complete after 2015 (68–86%) compared to prior (50–79%). Patient global, pain and fatigue assessments showed heterogeneity between registries in terms of wording, recall periods, and scale. Conclusion Important heterogeneity in registry design and data collection across fifteen European axSpA and PsA registries was observed. Several core measures were widely available, and an increase in data completeness of PROMs in recent years was identified. This study might serve as a basis for examining how differences in data collection across registries may impact the results of collaborative research in the future.

Published
2023
Full Text
View/download PDF

15. The management of patients with inflammatory bowel disease-associated spondyloarthritis: Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) and Italian Society of Rheumatology (SIR) recommendations based on a pseudo-Delphi consensus

Author

Macaluso, Fabio Salvatore, Caprioli, Flavio, Benedan, Laura, Bezzio, Cristina, Caporali, Roberto, Cauli, Alberto, Chimenti, Maria Sole, Ciccia, Francesco, D'Angelo, Salvatore, Fantini, Massimo Claudio, Festa, Stefano, Iannone, Florenzo, Lubrano, Ennio, Mariani, Paolo, Papi, Claudio, Provenzano, Giuseppe, Pugliese, Daniela, Rispo, Antonio, Saibeni, Simone, Salvarani, Carlo, Variola, Angela, Zenga, Mariangela, Armuzzi, Alessandro, Orlando, Ambrogio, and Gerli, Roberto

Published
2024
Full Text
View/download PDF

16. Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice

Author

Christiansen, Sara Nysom, Horskjær Rasmussen, Simon, Pons, Marion, Michelsen, Brigitte, Glintborg, Bente, Gudbjornsson, Bjorn, Grondal, Gerdur, Vencovsky, Jiri, Loft, Anne Gitte, Rotar, Ziga, Pirkmajer, Katja Perdan, Nissen, Michael J., Baranová, Jana, Macfarlane, Gary J., Jones, Gareth T., Iannone, Florenzo, Caporali, Roberto, Laas, Karin, Vorobjov, Sigrid, Giuseppe, Daniela Di, Olofsson, Tor, Provan, Sella Aarrestad, Fagerli, Karen Minde, Castrejon, Isabel, Otero-Varela, Lucia, van de Sande, Marleen, van der Horst-Bruinsma, Irene, Nordström, Dan, Kuusalo, Laura, Bernardes, Miguel, Hetland, Merete Lund, Østergaard, Mikkel, and Midtbøll Ørnbjerg, Lykke

Published
2024
Full Text
View/download PDF

17. Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies

Author

Lauper, Kim, Mongin, Denis, Bergstra, Sytske Anne, Choquette, Denis, Codreanu, Catalin, Gottenberg, Jacques-Eric, Kubo, Satoshi, Hetland, Merete Lund, Iannone, Florenzo, Kristianslund, Eirik K., Kvien, Tore K., Lukina, Galina, Mariette, Xavier, Nordström, Dan C., Pavelka, Karel, Pombo-Suarez, Manuel, Rotar, Ziga, Santos, Maria J., Tanaka, Yoshiya, Turesson, Carl, Courvoisier, Delphine S., Finckh, Axel, and Gabay, Cem

Published
2024
Full Text
View/download PDF

19. COVID-19 and Mixed Cryoglobulinemia Syndrome: Long-Term Survey Study on the Prevalence and Outcome, Vaccine Safety, and Immunogenicity

Author

Gragnani, Laura, Visentini, Marcella, Lorini, Serena, Santini, Stefano Angelo, Lauletta, Gianfranco, Mazzaro, Cesare, Urraro, Teresa, Quartuccio, Luca, Cacciapaglia, Fabio, Ruscitti, Piero, Tavoni, Antonio, Marri, Silvia, Cusano, Giuseppina, Petraccia, Luisa, Naclerio, Caterina, Treppo, Elena, del Frate, Giulia, Di Cola, Ilenia, Raimondo, Vincenzo, Scorpiniti, Daniela, Monti, Monica, Puccetti, Lorenzo, Elia, Giusy, Fallahi, Poupak, Basili, Stefania, Scarpato, Salvatore, Iannone, Florenzo, Casato, Milvia, Antonelli, Alessandro, Zignego, Anna Linda, and Ferri, Clodoveo

Published
2023
Full Text
View/download PDF

20. Musculoskeletal manifestations in children with Behçet’s syndrome: data from the AIDA Network Behçet’s Syndrome Registry

Author

Gaggiano, Carla, Maselli, Anna, Sfikakis, Petros P., Laskari, Katerina, Ragab, Gaafar, Hegazy, Mohamed Tharwat, Laymouna, Ahmed Hatem, Lopalco, Giuseppe, Almaghlouth, Ibrahim A., Asfina, Kazi Nur, Alahmed, Ohoud, Giardini Mayrink, Henrique Ayres, Parente de Brito Antonelli, Isabele, Cattalini, Marco, Piga, Matteo, Sota, Jurgen, Gentileschi, Stefano, Maggio, Maria Cristina, Opris-Belinski, Daniela, Hatemi, Gülen, Insalaco, Antonella, Olivieri, Alma Nunzia, Tufan, Abdurrahman, Karadeniz, Hazan, Kardaş, Riza Can, La Torre, Francesco, Cardinale, Fabio, Marino, Achille, Guerriero, Silvana, Ruscitti, Piero, Tarsia, Maria, Vitale, Antonio, Caggiano, Valeria, Telesca, Salvatore, Iannone, Florenzo, Parretti, Veronica, Frassi, Micol, Aragona, Emma, Ciccia, Francesco, Wiesik-Szewczyk, Ewa, Ionescu, Ruxandra, Şahin, Ali, Akkoç, Nurullah, Hinojosa-Azaola, Andrea, Tharwat, Samar, Hernández-Rodríguez, José, Espinosa, Gerard, Conti, Giovanni, Del Giudice, Emanuela, Govoni, Marcello, Emmi, Giacomo, Fabiani, Claudia, Balistreri, Alberto, Frediani, Bruno, Rigante, Donato, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

21. Safety outcomes in patients with rheumatoid arthritis treated with abatacept: results from a multinational surveillance study across seven European registries

Author

Alyssa Dominique, Merete Lund Hetland, Axel Finckh, Jacques-Eric Gottenberg, Florenzo Iannone, Roberto Caporali, Tzuyung Douglas Kou, Dan Nordstrom, Maria Victoria Hernandez, Carlos Sánchez-Piedra, Fernando Sánchez-Alonso, Karel Pavelka, T. Christopher Bond, and Teresa A. Simon

Subjects
Rheumatoid arthritis, Abatacept, Biologic DMARD, Safety, Infections, Malignancy, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background Patients with rheumatoid arthritis (RA) have an increased risk of infection and malignancy compared with the general population. Infection risk is increased further with the use of disease-modifying antirheumatic drugs (DMARDs), whereas evidence on whether the use of biologic DMARDs increases cancer risk remains equivocal. This single-arm, post-marketing study estimated the incidence of prespecified infection and malignancy outcomes in patients with RA treated with intravenous or subcutaneous abatacept. Methods Data were included from seven European RA quality registries: ATTRA (Anti-TNF Therapy in Rheumatoid Arthritis [Czech Republic]), DANBIO (Danish Rheumatologic Database), ROB-FIN (National Registry of Antirheumatic and Biological Treatment in Finland), ORA (Orencia and Rheumatoid Arthritis [France]), GISEA (Italian Group for the Study of Early Arthritis), BIOBADASER (Spanish Register of Adverse Events of Biological Therapies in Rheumatic Diseases), and the SCQM (Swiss Clinical Quality Management) system. Each registry is unique with respect to design, data collection, definition of the study cohort, reporting, and validation of outcomes. In general, registries defined the index date as the first day of abatacept treatment and reported data for infections requiring hospitalization and overall malignancies; data for other infection and malignancy outcomes were not available for every cohort. Abatacept exposure was measured in patient-years (p-y). Incidence rates (IRs) were calculated as the number of events per 1000 p-y of follow-up with 95% confidence intervals. Results Over 5000 patients with RA treated with abatacept were included. Most patients (78–85%) were female, and the mean age range was 52–58 years. Baseline characteristics were largely consistent across registries. Among patients treated with abatacept, IRs for infections requiring hospitalization across the registries ranged from 4 to 100 events per 1000 p-y, while IRs for overall malignancy ranged from 3 to 19 per 1000 p-y. Conclusions Despite heterogeneity between registries in terms of design, data collection, and ascertainment of safety outcomes, as well as the possibility of under-reporting of adverse events in observational studies, the safety profile of abatacept reported here was largely consistent with previous findings in patients with RA treated with abatacept, with no new or increased risks of infection or malignancy.

Published
2023
Full Text
View/download PDF

22. Explainable artificial intelligence for microbiome data analysis in colorectal cancer biomarker identification

Author

Pierfrancesco Novielli, Donato Romano, Michele Magarelli, Pierpaolo Di Bitonto, Domenico Diacono, Annalisa Chiatante, Giuseppe Lopalco, Daniele Sabella, Vincenzo Venerito, Pasquale Filannino, Roberto Bellotti, Maria De Angelis, Florenzo Iannone, and Sabina Tangaro

Subjects
machine learning, explainable artificial intelligence, colorectal cancer, microbiome, biomarker identification, microbiota, Microbiology, QR1-502
Abstract

BackgroundColorectal cancer (CRC) is a type of tumor caused by the uncontrolled growth of cells in the mucosa lining the last part of the intestine. Emerging evidence underscores an association between CRC and gut microbiome dysbiosis. The high mortality rate of this cancer has made it necessary to develop new early diagnostic methods. Machine learning (ML) techniques can represent a solution to evaluate the interaction between intestinal microbiota and host physiology. Through explained artificial intelligence (XAI) it is possible to evaluate the individual contributions of microbial taxonomic markers for each subject. Our work also implements the Shapley Method Additive Explanations (SHAP) algorithm to identify for each subject which parameters are important in the context of CRC.ResultsThe proposed study aimed to implement an explainable artificial intelligence framework using both gut microbiota data and demographic information from subjects to classify a cohort of control subjects from those with CRC. Our analysis revealed an association between gut microbiota and this disease. We compared three machine learning algorithms, and the Random Forest (RF) algorithm emerged as the best classifier, with a precision of 0.729 ± 0.038 and an area under the Precision-Recall curve of 0.668 ± 0.016. Additionally, SHAP analysis highlighted the most crucial variables in the model's decision-making, facilitating the identification of specific bacteria linked to CRC. Our results confirmed the role of certain bacteria, such as Fusobacterium, Peptostreptococcus, and Parvimonas, whose abundance appears notably associated with the disease, as well as bacteria whose presence is linked to a non-diseased state.DiscussionThese findings emphasizes the potential of leveraging gut microbiota data within an explainable AI framework for CRC classification. The significant association observed aligns with existing knowledge. The precision exhibited by the RF algorithm reinforces its suitability for such classification tasks. The SHAP analysis not only enhanced interpretability but identified specific bacteria crucial in CRC determination. This approach opens avenues for targeted interventions based on microbial signatures. Further exploration is warranted to deepen our understanding of the intricate interplay between microbiota and health, providing insights for refined diagnostic and therapeutic strategies.

Published
2024
Full Text
View/download PDF

23. Unraveling the microbiome-metabolome nexus: a comprehensive study protocol for personalized management of Behçet’s disease using explainable artificial intelligence

Author

Sabina Tangaro, Giuseppe Lopalco, Daniele Sabella, Vincenzo Venerito, Pierfrancesco Novielli, Donato Romano, Alessia Di Gilio, Jolanda Palmisani, Gianluigi de Gennaro, Pasquale Filannino, Rosanna Latronico, Roberto Bellotti, Maria De Angelis, and Florenzo Iannone

Subjects
explainable artificial intelligence, microbiome, volatilome, Behçet’s disease, gut, butyrate, Microbiology, QR1-502
Abstract

The presented study protocol outlines a comprehensive investigation into the interplay among the human microbiota, volatilome, and disease biomarkers, with a specific focus on Behçet’s disease (BD) using methods based on explainable artificial intelligence. The protocol is structured in three phases. During the initial three-month clinical study, participants will be divided into control and experimental groups. The experimental groups will receive a soluble fiber-based dietary supplement alongside standard therapy. Data collection will encompass oral and fecal microbiota, breath samples, clinical characteristics, laboratory parameters, and dietary habits. The subsequent biological data analysis will involve gas chromatography, mass spectrometry, and metagenetic analysis to examine the volatilome and microbiota composition of salivary and fecal samples. Additionally, chemical characterization of breath samples will be performed. The third phase introduces Explainable Artificial Intelligence (XAI) for the analysis of the collected data. This novel approach aims to evaluate eubiosis and dysbiosis conditions, identify markers associated with BD, dietary habits, and the supplement. Primary objectives include establishing correlations between microbiota, volatilome, phenotypic BD characteristics, and identifying patient groups with shared features. The study aims to identify taxonomic units and metabolic markers predicting clinical outcomes, assess the supplement’s impact, and investigate the relationship between dietary habits and patient outcomes. This protocol contributes to understanding the microbiome’s role in health and disease and pioneers an XAI-driven approach for personalized BD management. With 70 recruited BD patients, XAI algorithms will analyze multi-modal clinical data, potentially revolutionizing BD management and paving the way for improved patient outcomes.

Published
2024
Full Text
View/download PDF

24. Efficacy of canakinumab in patients with Still’s disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still’s Disease

Author

Antonio Vitale, Valeria Caggiano, Petros P. Sfikakis, Lorenzo Dagna, Giuseppe Lopalco, Gaafar Ragab, Francesco La Torre, Ibrahim A. Almaghlouth, Maria Cristina Maggio, Jurgen Sota, Abdurrahman Tufan, Andrea Hinojosa-Azaola, Florenzo Iannone, Roberta Loconte, Katerina Laskari, Haner Direskeneli, Piero Ruscitti, Maria Morrone, Henrique A. Mayrink Giardini, Alexandros Panagiotopoulos, Ilenia Di Cola, Eduardo Martín-Nares, Sara Monti, Ludovico De Stefano, Rıza Can Kardas, Rahime Duran, Corrado Campochiaro, Alessandro Tomelleri, Abdulaziz Mohammed Alabdulkareem, Carla Gaggiano, Maria Tarsia, Elena Bartoloni, Mery Romeo, Mohamed A. Hussein, Ahmed Hatem Laymouna, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Lampros Fotis, Sara Bindoli, Luca Navarini, Fatma Alibaz-Oner, Gizem Sevik, Micol Frassi, Francesco Ciccia, Daniela Iacono, Francesca Crisafulli, Piero Portincasa, Nour Jaber, Perla Ayumi Kawakami-Campos, Ewa Wiesik-Szewczyk, Annamaria Iagnocco, Gabriele Simonini, Paolo Sfriso, Alberto Balistreri, Roberto Giacomelli, Giovanni Conti, Bruno Frediani, Claudia Fabiani, and Luca Cantarini

Subjects
AOSD, AutoInflammatory diseases, rare diseases, personalized medicine, treatment, Medicine (General), R5-920
Abstract

IntroductionThe effectiveness of canakinumab may change according to the different times it is used after Still’s disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.MethodsPatients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still’s disease. Seventy-seven (51 females and 26 males) patients with Still’s disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.ResultsNo statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.ConclusionCanakinumab has proved to be effective in patients with Still’s disease, regardless of its line of biologic treatment.

Published
2023
Full Text
View/download PDF

25. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Clodoveo Ferri, Vincenzo Raimondo, Dilia Giuggioli, Laura Gragnani, Serena Lorini, Lorenzo Dagna, Silvia Laura Bosello, Rosario Foti, Valeria Riccieri, Serena Guiducci, Giovanna Cuomo, Antonio Tavoni, Rossella De Angelis, Fabio Cacciapaglia, Elisabetta Zanatta, Franco Cozzi, Giuseppe Murdaca, Ilaria Cavazzana, Nicoletta Romeo, Veronica Codullo, Roberta Pellegrini, Giuseppe Varcasia, Maria De Santis, Carlo Selmi, Giuseppina Abignano, Maurizio Caminiti, Massimo L'Andolina, Domenico Olivo, Ennio Lubrano, Amelia Spinella, Federica Lumetti, Giacomo De Luca, Piero Ruscitti, Teresa Urraro, Marcella Visentini, Silvia Bellando-Randone, Elisa Visalli, Davide Testa, Gabriella Sciascia, Francesco Masini, Greta Pellegrino, Francesca Saccon, Eugenia Balestri, Giusy Elia, Silvia Martina Ferrari, Antonio Tonutti, Francesca Dall’Ara, Giuseppa Pagano Mariano, Giorgio Pettiti, Giovanni Zanframundo, Raffaele Brittelli, Vincenzo Aiello, Ylenia Dal Bosco, Roberta Foti, Ilenia Di Cola, Daniela Scorpiniti, Enrico Fusaro, Tommaso Ferrari, Pietro Gigliotti, Corrado Campochiaro, Francesca Francioso, Carlo Iandoli, Virginia Caira, Anna Linda Zignego, Salvatore D'Angelo, Franco Franceschini, Marco Matucci-Cerinic, Roberto Giacomelli, Andrea Doria, Stefano Angelo Santini, Poupak Fallahi, Florenzo Iannone, and Alessandro Antonelli

Subjects
COVID-19, SARS-CoV-2, Systemic sclerosis, Scleroderma, Interstitial lung disease, COVID-19 vaccine, Immunologic diseases. Allergy, RC581-607
Abstract

Introduction: The impact of COVID-19 pandemic represents a serious challenge for ‘frail’ patients' populations with inflammatory autoimmune systemic diseases such as systemic sclerosis (SSc). We investigated the prevalence and severity of COVID-19, as well the effects of COVID-19 vaccination campaign in a large series of SSc patients followed for the entire period (first 38 months) of pandemic. Patients and method: This prospective survey study included 1755 unselected SSc patients (186 M, 1,569F; mean age 58.7 ± 13.4SD years, mean disease duration 8.8 ± 7.3SD years) recruited in part by telephone survey at 37 referral centers from February 2020 to April 2023. The following parameters were carefully evaluated: i. demographic, clinical, serological, and therapeutical features; ii. prevalence and severity of COVID-19; and iii. safety, immunogenicity, and efficacy of COVID-19 vaccines. Results: The prevalence of COVID-19 recorded during the whole pandemic was significantly higher compared to Italian general population (47.3 % vs 43.3 %, p

Published
2023
Full Text
View/download PDF

26. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study

Author

Bettiol, Alessandra, Urban, Maria Letizia, Padoan, Roberto, Groh, Matthieu, Lopalco, Giuseppe, Egan, Allyson, Cottin, Vincent, Fraticelli, Paolo, Crimi, Claudia, Del Giacco, Stefano, Losappio, Laura, Moi, Laura, Cinetto, Francesco, Caminati, Marco, Novikov, Pavel, Berti, Alvise, Cameli, Paolo, Cathébras, Pascal, Coppola, Angelo, Durel, Cécile-Audrey, Folci, Marco, Gullo, Alberto Lo, Lombardi, Carlo, Monti, Sara, Parronchi, Paola, Rivera, Carlos Martinez, Solans, Roser, Vacca, Angelo, Espígol-Frigolé, Georgina, Guarnieri, Gabriella, Bianchi, Fulvia Chieco, Marchi, Maria Rita, Tcherakian, Colas, Kahn, Jean-Emmanuel, Iannone, Florenzo, Venerito, Vincenzo, Desaintjean, Charlene, Moroncini, Gianluca, Nolasco, Santi, Costanzo, Giulia Anna Maria Luigia, Schroeder, Jan Walter, Ribi, Camillo, Tesi, Michelangelo, Gelain, Elena, Mattioli, Irene, Bello, Federica, Jayne, David, Prisco, Domenico, Vaglio, Augusto, and Emmi, Giacomo

Published
2023
Full Text
View/download PDF

27. Impact of COVID-19 and vaccination campaign on 1,755 systemic sclerosis patients during first three years of pandemic. Possible risks for individuals with impaired immunoreactivity to vaccine, ongoing immunomodulating treatments, and disease-related lung involvement during the next pandemic phase

Author

Ferri, Clodoveo, Raimondo, Vincenzo, Giuggioli, Dilia, Gragnani, Laura, Lorini, Serena, Dagna, Lorenzo, Bosello, Silvia Laura, Foti, Rosario, Riccieri, Valeria, Guiducci, Serena, Cuomo, Giovanna, Tavoni, Antonio, De Angelis, Rossella, Cacciapaglia, Fabio, Zanatta, Elisabetta, Cozzi, Franco, Murdaca, Giuseppe, Cavazzana, Ilaria, Romeo, Nicoletta, Codullo, Veronica, Pellegrini, Roberta, Varcasia, Giuseppe, De Santis, Maria, Selmi, Carlo, Abignano, Giuseppina, Caminiti, Maurizio, L'Andolina, Massimo, Olivo, Domenico, Lubrano, Ennio, Spinella, Amelia, Lumetti, Federica, De Luca, Giacomo, Ruscitti, Piero, Urraro, Teresa, Visentini, Marcella, Bellando-Randone, Silvia, Visalli, Elisa, Testa, Davide, Sciascia, Gabriella, Masini, Francesco, Pellegrino, Greta, Saccon, Francesca, Balestri, Eugenia, Elia, Giusy, Ferrari, Silvia Martina, Tonutti, Antonio, Dall’Ara, Francesca, Pagano Mariano, Giuseppa, Pettiti, Giorgio, Zanframundo, Giovanni, Brittelli, Raffaele, Aiello, Vincenzo, Dal Bosco, Ylenia, Foti, Roberta, Di Cola, Ilenia, Scorpiniti, Daniela, Fusaro, Enrico, Ferrari, Tommaso, Gigliotti, Pietro, Campochiaro, Corrado, Francioso, Francesca, Iandoli, Carlo, Caira, Virginia, Zignego, Anna Linda, D'Angelo, Salvatore, Franceschini, Franco, Matucci-Cerinic, Marco, Giacomelli, Roberto, Doria, Andrea, Santini, Stefano Angelo, Fallahi, Poupak, Iannone, Florenzo, and Antonelli, Alessandro

Published
2023
Full Text
View/download PDF

28. Expert consensus on the treatment of patients with adult-onset still's disease with the goal of achieving an early and long-term remission

Author

Belfiore, Norma, Bernardi, Cristina, Gabini, Marco, Bettio, Silvano, Brucato, Antonio, Italiano, Giovanni, Cantatore, Francesco Paolo, Iacono, Daniela, Pantano, Ilenia, Tirri, Enrico, Ursini, Francesco, Monaco, Andrea Lo, Caso, Francesco, Quartuccio, Luca, Chimenti, Maria Sole, Gattamelata, Angelica, Gremese, Elisa, Paroli, Marino, Picchianti-Diamanti, Andrea, Sebastiani, Gian Domenico, Favalli, Ennio, Sulli, Alberto, Frassi, Micol, Faggioli, Paola, Foti, Rosario, Campochiaro, Corrado, Cavalli, Giulio, Tomelleri, Alessandro, Manara, Maria, De Stefano, Ludovico, De Angelis, Rossella, Parisi, Simone, Lopalco, Giuseppe, Piga, Matteo, Marotto, Daniela, Colaci, Michele, Padula, Angela, Guggino, Giuliana, Emmi, Giacomo, Baldini, Chiara, Sota, Jurgen, Vitale, Antonio, Berti, Alvise, Bartoloni, Elena, Grava, Chiara, Bindoli, Sara, Vitetta, Rosetta, Giacomelli, Roberto, Caporali, Roberto, Ciccia, Francesco, Colafrancesco, Serena, Dagna, Lorenzo, Govoni, Marcello, Iannone, Florenzo, Leccese, Pietro, Montecucco, Carlomaurizio, Pappagallo, Giovanni, Pistone, Giovanni, Priori, Roberta, Ruscitti, Piero, Sfriso, Paolo, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

29. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Author

Michelsen, Brigitte, Østergaard, Mikkel, Nissen, Michael John, Ciurea, Adrian, Möller, Burkhard, Ørnbjerg, Lykke Midtbøll, Zavada, Jakub, Glintborg, Bente, MacDonald, Alan, Laas, Karin, Nordström, Dan, Gudbjornsson, Bjorn, Iannone, Florenzo, Hellmand, Pasoon, Kvien, Tore Kristian, Rodrigues, Ana Maria, Codreanu, Catalin, Rotar, Ziga, Castrejón Fernández, Isabel, Wallman, Johan Karlsson, Vencovsky, Jiri, Loft, Anne Gitte, Heddle, Maureen, Vorobjov, Sigrid, Hokkanen, Anna-Mari, Gröndal, Gerdur, Sebastiani, Marco, van de Sande, Marleen, Kristianslund, Eirik Klami, Santos, Maria José, Mogosan, Corina, Tomsic, Matija, Díaz-González, Federico, Di Giuseppe, Daniela, and Hetland, Merete Lund

Published
2023
Full Text
View/download PDF

31. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists

Author

Salvatore D’Angelo, Fabiola Atzeni, Maurizio Benucci, Gerolamo Bianchi, Fabrizio Cantini, Roberto Felice Caporali, Giorgio Carlino, Francesco Caso, Alberto Cauli, Francesco Ciccia, Maria Antonietta D’Agostino, Lorenzo Dagna, Christian Dejaco, Oscar Massimiliano Epis, Maria Grazia Ferrucci, Franco Franceschini, Enrico Fusaro, Marco Gabini, Roberto Gerli, Roberto Giacomelli, Marcello Govoni, Elisa Gremese, Giuliana Guggino, Annamaria Iagnocco, Florenzo Iannone, Bruno Laganà, Ennio Lubrano, Carlomaurizio Montecucco, Rosario Peluso, Roberta Ramonda, Maurizio Rossini, Carlo Salvarani, Gian Domenico Sebastiani, Marco Sebastiani, Carlo Selmi, Enrico Tirri, and Antonio Marchesoni

Subjects
psoriatic arthritis, chronic inflammatory musculoskeletal disease, comorbidities, extra-articular manifestations, diagnosis, treatment, Medicine (General), R5-920
Abstract

BackgroundPsoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disease involving several articular and extra-articular structures. Despite the important progresses recently made in all of the aspects of this disease, its management is still burdened by unresolved issues. The aim of this exercise was to provide a set of statements that may be helpful for the management of PsA.MethodsA group of 38 Italian rheumatologists with recognized expertise in PsA selected and addressed the following four topics: “early PsA,” “axial-PsA,” “extra-articular manifestations and comorbidities,” “therapeutic goals.” Relevant articles from the literature (2016–2022) were selected by the experts based on a PubMed search. A number of statements for each topic were elaborated.ResultsNinety-four articles were selected and evaluated, 68 out of the 1,114 yielded by the literature search and 26 added by the Authors. Each of the four topic was subdivided in themes as follows: transition from psoriasis to PsA, imaging vs. CASPAR criteria in early diagnosis, early treatment for “early PsA”; axial-PsA vs. axialspondyloarthritis, diagnosis, clinical evaluation, treatment, standard radiography vs. magnetic resonance imaging for “axial PsA”; influence of inflammatory bowel disease on the therapeutic choice, cardiovascular comorbidity, bone damage, risk of infection for “comorbidities and extra-articular manifestations”; target and tools, treat-to-target strategy, role of imaging for “therapeutic goals.” The final document consisted of 49 statements.DiscussionThe final product of this exercise is a set of statements concerning the main issues of PsA management offering an expert opinion for some unmet needs of this complex disease.

Published
2023
Full Text
View/download PDF

32. Still’s disease continuum from childhood to elderly: data from the international AIDA Network Still’s disease registry

Author

Micol Frassi, Marcello Govoni, Annamaria Iagnocco, Florenzo Iannone, Paola Triggianese, Corrado Campochiaro, Sara Monti, Maria G Tektonidou, Eduardo Martin-Nares, Piero Ruscitti, Roberto Giacomelli, Luca Cantarini, Giuseppe Lopalco, Lorenzo Dagna, Francesco Carubbi, Alma Nunzia Olivieri, Antonio Vitale, Ombretta Viapiana, Fatma Alibaz-Öner, Haner Direskeneli, Petros P Sfikakis, Giacomo Emmi, Claudia Fabiani, Gabriele Simonini, Francesco Ciccia, Elena Bartoloni, Alessandro Tomelleri, Daniela Iacono, Riza Can Kardas, Bruno Frediani, Benson Ogunjimi, Amato de Paulis, Onorina Berardicurti, Alessandro Conforti, Ilenia Di Cola, Anastasios Karamanakos, Katerina Laskari, Abdurrahman Tufan, Stefania Costi, José Hernández-Rodríguez, Lampros Fotis, Jurgen Sota, Antonio Gidaro, Ewa Wiesik-Szewczyk, Gian Domenico Sebastiani, Jiram Torres-Ruiz, Paolo Sfriso, Giovanni Conti, Luca Navarini, Francesco La Torre, Samar Tharwat, Andrea Hinojosa-Azaola, Alberto Lo Gullo, Valeria Caggiano, Ibrahim A Almaghlouth, Kazi Asfina, Gafaar Ragab, Maria Cristina Maggio, Joanna Makowska, Emanuela Del Giudice, Armin Maier, Sukran Erten, Henrique A Mayrink Giardini, Maria Morrone, Isabele Parente de Brito Antonelli, Marilia Ambiel Dagostin, Martina Patrone, Fehaid Alanazi, Carla Gaggiano, Hamit Kucuk, Ayman Abdel-Monem Ahmed Mahmoud, Katerina Kourtesi, Maria Tarsia, Verónica Gómez-Caverzaschi, Angela Mauro, and Alberto Balistreri

Subjects
Medicine
Abstract

Objective Still’s disease is more frequently observed in the paediatric context, but a delayed onset is not exceptional both in the adulthood and in the elderly. However, whether paediatric-onset, adult-onset and elderly-onset Still’s disease represent expressions of the same disease continuum or different clinical entities is still a matter of controversy. The aim of this study is to search for any differences in demographic, clinical features and response to treatment between pediatric-onset, adult-onset and elderly-onset Still’s disease.Methods Subjects included in this study were drawn from the International AutoInflammatory Disease Alliance Network registry for patients with Still’s disease.Results A total of 411 patients suffering from Still’s disease were enrolled; the disease occurred in the childhood in 65 (15.8%) patients, in the adult 314 (76.4%) patients and in the elderly in 32 (7.8%) patients. No statistically significant differences at post-hoc analysis were observed in demographic features of the disease between pediatric-onset, adult-onset and elderly-onset Still’s disease. The salmon-coloured skin rash (p=0.004), arthritis (p=0.009) and abdominal pain (p=0.007) resulted significantly more frequent among paediatric patients than in adult cases, while pleuritis (p=0.015) and arthralgia (p

Published
2023
Full Text
View/download PDF

33. Sex differences in the effectiveness of first-line tumour necrosis factor inhibitors in axial spondyloarthritis: results from the EuroSpA Research Collaboration Network

Author

Ronald F van Vollenhoven, Bente Glintborg, Merete Lund Hetland, Ulf Lindström, Brigitte Michelsen, Elsa Vieira-Sousa, Florenzo Iannone, Eirik Klami Kristianslund, Dan Nordström, Karel Pavelka, Ziga Rotar, Maria Jose Santos, Catalin Codreanu, Gary J Macfarlane, Mikkel Østergaard, Michael T Nurmohamed, Jiri Vencovsky, Rosario Foti, Bjorn Gudbjornsson, Matija Tomšič, Lykke Midtbøll Ørnbjerg, Adrian Ciurea, Árni Jón Geirsson, Irene van der Horst-Bruinsma, Michael S Nissen, Ovidiu Rotariu, Isabel Castrejón, Johan K Wallman, Marleen van de Sande, Anne G Loft, Pasoon Hellamand, Thomas Klausch, Anna Mari Hokkanen, Corina Mogosan, Lucia Otero-Varela, Semih Gulle, and Berrin Zengin

Subjects
Medicine
Abstract

Objective Evidence indicates reduced treatment effectiveness of TNFi in women with axial spondyloarthritis (axSpA) compared with men. We aimed to investigate sex differences in treatment response and retention rates over 24 months of follow-up in axSpA patients initiating their first TNFi.Methods Data from axSpA patients initiating a TNFi in 1 of 15 registries within EuroSpA collaboration were pooled. We investigated the association of sex with treatment response using logistic regression. The primary outcome was clinically important improvement (CII) at 6 months according to Ankylosing Spondylitis Disease Activity Score with C-reactive protein (CRP) (≥1.1 decrease). We adjusted for age, country and TNFi start year. A secondary outcome was retention rates over 24 months of follow-up assessed by Kaplan-Meier estimator.Results In total, 6451 axSpA patients with data on CII were assessed for treatment response; 2538 (39%) were women and 3913 (61%) were men. Women presented at baseline with lower CRP levels but had higher scores on patient-reported outcome measures. At 6 months, 53% of the women and 66% of the men had CII. Women had a lower relative risk of CII compared with men (0.81; 95% CI 0.77 to 0.84). This sex difference was similar in adjusted analysis (0.85; 95% CI 0.82 to 0.88). Retention rates were evaluated in 27 702 patients. The TNFi 6/12/24 months retention rates were significantly lower among women (79%/66%/53%) than men (88%/79%/69%).Conclusion Treatment response and retention rates are lower among women with axSpA initiating their first TNFi. Sex differences in treatment effectiveness were present regardless of the outcome measure used for treatment response, and differences in retention rates transpired early and increased as time progressed.

Published
2023
Full Text
View/download PDF

34. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

Author

Brigitte Michelsen, Mikkel Østergaard, Michael John Nissen, Adrian Ciurea, Burkhard Möller, Lykke Midtbøll Ørnbjerg, Jakub Zavada, Bente Glintborg, Alan MacDonald, Karin Laas, Dan Nordström, Bjorn Gudbjornsson, Florenzo Iannone, Pasoon Hellmand, Tore Kristian Kvien, Ana Maria Rodrigues, Catalin Codreanu, Ziga Rotar, Isabel Castrejón Fernández, Johan Karlsson Wallman, Jiri Vencovsky, Anne Gitte Loft, Maureen Heddle, Sigrid Vorobjov, Anna-Mari Hokkanen, Gerdur Gröndal, Marco Sebastiani, Marleen van de Sande, Eirik Klami Kristianslund, Maria José Santos, Corina Mogosan, Matija Tomsic, Federico Díaz-González, Daniela Di Giuseppe, and Merete Lund Hetland

Subjects
Health policy, Psoriatic arthritis, Axial spondyloarthritis, Treatment recommendations, Public aspects of medicine, RA1-1270
Abstract

Summary: This is the first report comparing EULAR and national treatment recommendations for PsA patients across Europe, and the first this decade to compare ASAS-EULAR and national treatment recommendations in axSpA patients. An electronic survey was completed from October 2021–April 2022 by rheumatologists in 15 European countries. One and four countries followed all EULAR and ASAS-EULAR recommendations, respectively. Five countries had no national treatment recommendations for PsA and/or axSpA, but followed other regulations. In several countries, national treatment recommendations predated the most recent EULAR/ASAS-EULAR recommendations. Entry criteria for starting biologic/targeted synthetic disease-modifying anti-rheumatic drugs varied considerably. In several countries, for PsA patients with significant skin involvement, interleukin-17 inhibitors were not given preference. The positioning of Janus Kinase inhibitors differed and Phosphodiesterase-4 inhibitors were not in use/reimbursed in most countries. This study may motivate European countries to update their national treatment recommendations, to align them better with the latest international recommendations.

Published
2023
Full Text
View/download PDF

36. Multiparametric autoantibody analysis: a new paradigm for the diagnosis of connective tissue diseases

Author

Nicola Bizzaro, Danilo Villalta, Vittorio Bini, Paola Migliorini, Franco Franceschini, Silvia Piantoni, Emirena Garrafa, Valeria Riccieri, Antonella Fioravanti, Francesca Bellisai, Marilina Tampoia, Marco Fornaro, Florenzo Iannone, Anna Ghirardello, Margherita Zen, Boaz Palterer, Paola Parronchi, Maria Infantino, Maurizio Benucci, Amelia Rigon, Luisa Arcarese, Stefania Del Rosso, Valentina Canti, Elena Bartoloni, Roberto Gerli, and FIRMA Collaborators

Subjects
Connective tissue diseases, Multiplex testing, Autoantibody profiling, Particle-based multi-analyte technology, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background In patients affected by connective tissue diseases (CTDs), the identification of wide autoantibody profiles may prove useful in early diagnosis, in the evaluation of prognosis (risk stratification), and in predicting response to therapy. The aim of the present study was to evaluate the utility of multiparametric autoantibody analysis performed by a new fully automated particle-based multi-analyte technology (PMAT) digital system in a large multicenter cohort of CTD patients and controls. Methods Serum samples from 787 patients with CTD (166 systemic lupus erythematosus; 133 systemic sclerosis; 279 Sjögren’s syndrome; 106 idiopathic inflammatory myopathies; 103 undifferentiated CTD), 339 patients with other disorders (disease controls) (118 infectious diseases, 110 organ-specific autoimmune diseases, 111 other rheumatic diseases), and 121 healthy subjects were collected in 13 rheumatologic centers of the FIRMA group. Sera were analyzed with the Aptiva-PMAT instrument (Inova Diagnostics) for a panel of 29 autoantibodies. Results Multiparametric logistic regression showed that enlarged antibody profiles have a higher diagnostic efficiency than that of individual antibodies or of antibodies that constitute classification criteria for a given disease and that probability of disease increases with multiple positive autoantibodies. Conclusions This is the first study that analyzes the clinical and diagnostic impact of autoantibody profiling in CTD. The results obtained with the new Aptiva-PMAT method may open interesting perspectives in the diagnosis and sub-classification of patients with autoimmune rheumatic diseases.

Published
2022
Full Text
View/download PDF

37. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study

Author

Emanuela Zagni, Micol Frassi, Giuseppa Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Alessandro Zullo, Lucia Simoni, Martina Fiocchi, Roberto Orsenigo, and Delia Colombo

Subjects
Psoriatic arthritis, Biologics, Tumor necrosis factor, Secukinumab, Costs, Cost-per-responder, Public aspects of medicine, RA1-1270
Abstract

Abstract Background Psoriatic arthritis (PsA) is a chronic, immune-mediated, spondyloarthropathy characterised by musculoskeletal signs and symptoms with associated joint pain and tenderness. The average worldwide PsA prevalence is 133/100,000, while in the Italian population is 90–420/100,000. Traditionally, nonsteroidal anti-inflammatory drugs, glucocorticoid, and disease-modifying antirheumatic drugs have been used in the treatment of PsA. However, for those patients who are not adequately controlled with conventional therapies, the new biologics compounds represent a valid option. Biologic therapies have been shown to be more effective but also more expensive than conventional systemic treatments. Based on the CHRONOS study, the economic analyses presented in this paper aim to assess the annualised direct costs and the cost-per-responder of biologics in a real-world context assuming the Italian National Health System perspective. Methods The economic assessments were carried out on the overall cohort of patients, and on the tumour necrosis factor alpha inhibitors (TNFi) and the secukinumab subgroup, the most prescribed biologic therapies within the CHRONOS study. Results The annual economic impact of PsA in the overall group was €12,622, €11,725 in the secukinumab subgroup, and €12,791 in the TNFi subgroup. Biologics absorbed the main expenditure costs in the treatment of PsA accounting for about the 93% of total costs. At 6 months, secukinumab performed better in all the considered outcomes: cost-per-responder according to EULAR DAS28 and ACR50 response criteria were €12,661- €28,975, respectively, while they were €13,356 - €33,368 in the overall cohort and €13,138 - €35,166 in the TNFi subgroup. At 12 months secukinumab remained the subgroup with the lowest cost-per-responder ratio in EULAR DAS28 and ACR50 response criteria, while TNFi subgroup was the lowest one considered the ACR20. Conclusion Despite some potential methodological limitations, our cost-per-response analysis provides physicians and payers additional insights which can complement the traditional risk-benefit profile assessment and drive treatment decisions.

Published
2022
Full Text
View/download PDF

38. Systemic sclerosis sine scleroderma: clinical and serological features and relationship with other cutaneous subsets in a large series of patients from the national registry ‘SPRING’ of the Italian Society for Rheumatology

Author

Carlo Alberto Scirè, Andrea Doria, Marcello Govoni, Gerolamo Bianchi, Marco Matucci-Cerinic, Florenzo Iannone, Ennio Lubrano, Corrado Campochiaro, Veronica Codullo, Alessandra Della Rossa, Gemma Lepri, Elisabetta Zanatta, Beretta Lorenzo, Doria Andrea, Lepri Gemma, Lorenzo Beretta, Greta Carrara, Alarico Ariani, Simone Parisi, Marta Saracco, Francesco Girelli, Maria De Santis, Federica Lumetti, Dilia Giuggioli, Enrico Fusaro, Simone Barsotti, Ilaria Cavazzana, Federica Furini, Carlo Salvarani, Serena Guiducci, Franco Cozzi, Valeria Riccieri, Francesca Ingegnoli, Edoardo Rosato, Antonietta Gigante, Rosario Foti, Elisa Visalli, Fabio Cacciapaglia, Lorenzo Dagna, Franco Franceschini, Silvia Bellando-Randone, Giovanna Cuomo, Gianluigi Bajocchi, Alessandro Giollo, Giacomo De Luca, Giuseppina Abignano, Carlo Sciré, Anna Zanetti, Giovanni Zanframundo, Edoardo Cipolletta, Silvia Laura Bosello, Clodoveo Ferri, Amelia Spinella, Giuseppa Pagano Mariano, Maurizio Caminiti, Giuseppe Murdaca, Salvatore D'Angelo, Gianpiero Landolfi, Nicoletta Romeo, Gian Domenico Sebastiani, Erika Pigatto, Rossella De Angelis, Davide Rozza, Maria-Grazia Lazzaroni, Anna Maria Iuliano, Giovanni Ciano, Gianluca Bagnato, Ilenia De Andres, Cecilia Agnes, Luca Magnani, Claudio Di Vico, Greta Pellagrino, Elena Generali, Gianna Mennillo, Licia Vultaggio, Clara Lisa Peroni, Abignano Giuseppina, Agnes Cecilia, Amato Giorgio, Ariani Alarico, Bagnato Gianluca, Bajoicchi Gianluigi, Barsotti Simone, Bellando-Randone Silvia, Benenati Alessia, Bianchi Gerolamo, Bosello Silvia, Cacciapaglia Fabio, Calabrese Francesca, Caminiti Maurizio, Campochiaro Corrado, Carignola Renato, Ciano Giovanni, Cipolletta Edoardo, Codullo Veronica, Cozzi Franco, Cuomo Giovanna, D’Angelo Salvatore, Dagna Lorenzo, Dall’Ara Francesca, De Andres Ilenia, De Angelis Rossella, De Cata Angelo, De Luca Giacomo, De Santis Maria, Della Rossa Alessandra, Di Vico Claudio, Doveri Marica, Foti Rosario, Furini Federica, Fusaro Enrico, Generali Elena, Gigante Antonietta, Giollo Alessandro, Girelli Francesco, Giuggioli Dilia, Govoni Marcello, Guiducci Serena, Iannone Florenzo, Ingegnoli Francesca, Iuliano Anna Maria, Lazzaroni Maria Grazia, Lubrano Ennio, Lumetti Federica, Magnani Luca, Mennillo Gianna, Murdaca Giuseppe Ospedale, Pagano Mariano Giuseppa, Parisi Simone, Pellegrino Greta, Peroni Clara Lisa, Pigatto Erika, Riccieri Valeria, Romeo Nicoletta, Rosato Edoardo, Sambataro Gianluca, Saracco Marta, Sebastiani Giandomenico, Spinella Amelia, Talotta Rossella, Visalli Elisa, Vultaggio Licia, Zanatta Elisabetta, and Zanframundo Giovanni

Subjects
Medicine
Abstract

Objective To describe demographic, clinical and laboratory features of systemic sclerosis sine scleroderma (ssSSc) in a large multicentre systemic sclerosis (SSc) cohort.Methods Data involving 1808 SSc patients from Italian Systemic sclerosis PRogression INvestiGation registry were collected. The ssSSc was defined by the absence of any cutaneous sclerosis and/or puffy fingers. Clinical and serological features of ssSSc were compared with limited cutaneous (lcSSc) and diffuse cutaneous (dcSSc) subsets.Results Among patients with SSc, only 61 (3.4%) were classified as having ssSSc (F/M=19/1). Time from Raynaud’s phenomenon (RP) onset to diagnosis was longer in ssSSc (3 years, IQR 1–16.5) than lcSSc (2 years, IQR 0–7), and dcSSc (1 year, IQR 0–3) (p

Published
2023
Full Text
View/download PDF

39. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Vacca, Alessandra, Giollo, Alessandro, Balbir-Gurman, Alexandra, Gheorghiu, Ana Maria, Marcoccia, Antonella, Herrick, Ariane, Radic, Mislav, Stamenkovic, Bojana, Anic, Branimir, Granel, Brigitte, Ribi, Camillo, Selmi, Carlo Francesco, Carlos de la Puente, Milano, de Souza Müller, Carolina, Denton, Christopher, Kayser, Cristiane, Tanaseanu, Cristina-Mihaela, Majewski, Dominik, Rimar, Doron, Krasowska, Dorota, Veale, Douglas, Walker, Ulrich, Kerzberg, Eduardo, Rezus, Elena, Zanatta, Elisabetta, Siegert, Elise, De Langhe, Ellen, Oksel, Fahrettin, Ingegnoli, Francesca, Cantatore, Francesco Paolo, Szücs, Gabriela, Cuomo, Giovanna, Seskute, Goda, Litinsky, VilniusIra, Castellví, Ivan, Morovic-Vergles, Jadranka, Sibilia, Jean, Henes, Jörg, Solanki, Kamal, Perdan-Pirkmajer, Katja, Herrmann, Kristine, Saketkoo, Lesley Ann, Stamp, Lisa, Mouthon, Luc, Salvador, Maria João, Pozzi, Maria Rosa, Üprus, Maria, Vanthuyne, Marie, Engelhart, Merete, Köhm, Michaela, Iudici, Michele, Inanc, Murat, Fathi, Nihal, Pamuk, Nuri, García de la Peña Lefebv, Paloma, Carreira, Patricia E., Bancel, Dominique Farge, Moroncini, Luca, Montecucco, C., Ancuta, Codrina, Sunderkötter, Cord, Müller-Ladner, Ulf, Rosato, Edoardo, Kucharz, Eugene J., Iannone, Florenzo, Del Galdo, Francesco, Poormoghim, Hadi, Kötter, Ina, Distler, Jörg, Cutolo, Maurizio, Tikly, Mohammed, Damjanov, Nemanja, Hunzelmann, Nicolas, Vlachoyiannopoulos, P., Hasler, Paul, Sarzi Puttini, Piercarlo, Wiland, Piotr, Becvar, Radim, Yavuz, Sule, Zdrojewski, Zbigniew, Pellerito, Raffaele, Foti, Rosario, Ionescu, Ruxandra Maria, Adler, Sabine, Kahl, Sarah, Moiseev, Sergey, Stebbings, Simon, Rednic, Simona, Negrini, Simone, Heitmann, Stefan, Ullman, Susanne, Agachi, Svetlana, Martin, Thierry, Schmeiser, Tim, Riccieri, Valeria, Smith, Vanessa, Bernardino, Vera, Ortiz-Santamaria, Vera, Hsu, Vivien M., Abdel Atty Mohamed, Walid Ahmed, Hoffmann-Vold, Anna-Maria, Brunborg, Cathrine, Airò, Paolo, Ananyeva, Lidia P., Czirják, László, Guiducci, Serena, Hachulla, Eric, Li, Mengtao, Mihai, Carina, Riemekasten, Gabriela, Sfikakis, Petros P., Valentini, Gabriele, Kowal-Bielecka, Otylia, Allanore, Yannick, and Distler, Oliver

Published
2023
Full Text
View/download PDF

40. Development and implementation of the AIDA International Registry for patients with Behçet’s disease

Author

Vitale, Antonio, Della Casa, Francesca, Ragab, Gaafar, Almaghlouth, Ibrahim A., Lopalco, Giuseppe, Pereira, Rosa Maria, Guerriero, Silvana, Govoni, Marcello, Sfikakis, Petros P., Giacomelli, Roberto, Ciccia, Francesco, Monti, Sara, Ruscitti, Piero, Piga, Matteo, Lomater, Claudia, Tufan, Abdurrahman, Opris-Belinski, Daniela, Emmi, Giacomo, Hernández-Rodríguez, José, Şahin, Ali, Sebastiani, Gian Domenico, Bartoloni, Elena, Akkoç, Nurullah, Gündüz, Özgül Soysal, Cattalini, Marco, Conti, Giovanni, Hatemi, Gulen, Maier, Armin, Parronchi, Paola, Del Giudice, Emanuela, Erten, Sukran, Insalaco, Antonella, Li Gobbi, Francesca, Maggio, Maria Cristina, Shahram, Farhad, Caggiano, Valeria, Hegazy, Mohamed Tharwat, Asfina, Kazi Nur, Morrone, Maria, Prado, Leandro L., Dammacco, Rosanna, Ruffilli, Francesca, Arida, Aikaterini, Navarini, Luca, Pantano, Ilenia, Cavagna, Lorenzo, Conforti, Alessandro, Cauli, Alberto, Marucco, Elena Maria, Kucuk, Hamit, Ionescu, Ruxandra, Mattioli, Irene, Espinosa, Gerard, Araújo, Olga, Karkaş, Burak, Canofari, Claudia, Sota, Jurgen, Laymouna, Ahmed Hatem, Bedaiwi, Asma. A., Colella, Sergio, Giardini, Henrique Ayres M., Albano, Valeria, Lo Monaco, Andrea, Fragoulis, George E., Kardas, Riza Can, Berlengiero, Virginia, Hussein, Mohamed A., Ricci, Francesca, La Torre, Francesco, Rigante, Donato, Więsik-Szewczyk, Ewa, Frassi, Micol, Gentileschi, Stefano, Tosi, Gian Marco, Dagostin, Marilia Ambiel, Mahmoud, Ayman Abdel-Monem Ahmed, Tarsia, Maria, Alessio, Giovanni, Cimaz, Rolando, Giani, Teresa, Gaggiano, Carla, Iannone, Florenzo, Cipriani, Paola, Mourabi, Mariam, Spedicato, Veronica, Barneschi, Sara, Aragona, Emma, Balistreri, Alberto, Frediani, Bruno, Fabiani, Claudia, and Cantarini, Luca

Published
2022
Full Text
View/download PDF

42. The administration of methotrexate in patients with Still's disease, “real-life” findings from AIDA Network Still Disease Registry

Author

Ruscitti, Piero, Sota, Jurgen, Vitale, Antonio, Lopalco, Giuseppe, Iannone, Florenzo, Morrone, Maria, Giardini, Henrique Ayres Mayrink, D'Agostin, Marília Ambuel, Antonelli, Isabelle Parente de Brito, AlMaghlouth, Ibrahim, Asfina, Kazi Nur, Khalil, Najma, Sfikakis, Petros P., Laskari, Katerina, Tektonidou, Maria, Ciccia, Francesco, Iacono, Daniela, Riccio, Flavia, Ragab, Gaafar, Hussein, Mohamed A., Govoni, Marcello, Ruffilli, Francesca, Direskeneli, Haner, Alibaz-Oner, Fatma, Giacomelli, Roberto, Navarrini, Luca, Bartoloni, Elena, Riccucci, Ilenia, Martín-Nares, Eduardo, Torres-Ruiz, Jiram, Cipriani, Paola, Cola, Ilenia Di, Hernández-Rodríguez, José, Gómez-Caverzaschi, Verónica, Dagna, Lorenzo, Tomelleri, Alessandro, Makowska, Joanna, Brzezinska, Olga, Iagnocco, Annamaria, Bellis, Elisa, Caggiano, Valeria, Gaggiano, Carla, Tarsia, Maria, Mormile, Ilaria, Emmi, Giacomo, Sfriso, Paolo, Monti, Sara, Erten, Şükran, Giudice, Emanuela Del, Lubrano, Riccardo, Conti, Giovanni, Olivieri, Alma Nunzia, Gullo, Alberto Lo, Tharwat, Samar, Karamanakos, Anastasios, Gidaro, Antonio, Maggio, Maria Cristina, La Torre, Francesco, Cardinale, Fabio, Ogunjimi, Benson, Maier, Armin, Sebastiani, Gian Domenico, Opris-Belinski, Daniela, Frassi, Micol, Viapiana, Ombretta, Bizzi, Emanuele, Carubbi, Francesco, Fotis, Lampros, Tufan, Abdurrahman, Kardas, Riza Can, Więsik-Szewczyk, Ewa, Jahnz-Różyk, Karina, Fabiani, Claudia, Frediani, Bruno, Balistreri, Alberto, Rigante, Donato, and Cantarini, Luca

Published
2023
Full Text
View/download PDF

43. Accrual of organ damage in Behçet’s syndrome: trajectory, associated factors, and impact on patients’ quality of life over a 2-year prospective follow-up study

Author

Alberto Floris, Matteo Piga, Riccardo Laconi, Gerard Espinosa, Giuseppe Lopalco, Luisa Serpa Pinto, Nikolaos Kougkas, Jurgen Sota, Andrea Lo Monaco, Marcello Govoni, Luca Cantarini, George Bertsias, João Correia, Florenzo Iannone, Ricard Cervera, Carlos Vasconcelos, Alessandro Mathieu, and Alberto Cauli

Subjects
Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background This study aimed to investigate the trajectory of damage accrual, associated factors, and impact on health-related quality of life (HR-QoL) in a multicenter cohort of patients with Behçet’s syndrome (BS) over 2 years of follow-up. Methods Patients recruited in the BS Overall Damage Index (BODI) validation study were prospectively monitored for 2 years and assessed for damage accrual, defined as an increase ≥1 in the BODI score, and HR-QoL was evaluated by the SF-36 questionnaire. Logistic and multiple linear regression models were built to determine factors associated with damage accrual and impairment in the different SF-36 domains. Results During follow-up, 36 out of 189 (19.0%) patients had an increase ≥1 in the BODI score with a mean (SD) difference of 1.7 (0.8) (p

Published
2022
Full Text
View/download PDF

44. Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriatic artHRitis in Italy: an ObservatioNal lOngitudinal Study of real-life clinical practice) observational longitudinal study

Author

Delia Colombo, Micol Frassi, Giusy Pagano Mariano, Enrico Fusaro, Claudia Lomater, Patrizia Del Medico, Florenzo Iannone, Rosario Foti, Massimiliano Limonta, Antonio Marchesoni, Bernd Raffeiner, Ombretta Viapiana, Walter Grassi, Rosa Daniela Grembiale, Giuliana Guggino, Antonino Mazzone, Enrico Tirri, Roberto Perricone, Pier Carlo Sarzi Puttini, Salvatore De Vita, Fabrizio Conti, Alessandra Ori, Lucia Simoni, Martina Fiocchi, Roberto Orsenigo, Emanuela Zagni, and and the CHRONOS Study Group

Subjects
Psoriatic arthritis, Biologics, Real world evidence, ACR, DAS28, Secukinumab, Diseases of the musculoskeletal system, RC925-935
Abstract

Abstract Background Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice. Methods CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics. Results 399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.5) months. The most frequently prescribed biologic was secukinumab (40.4%), followed by adalimumab (17.8%) and etanercept (16.5%). The proportion of overall responders according to EULAR DAS28 criteria was 71.8% (95% CI: 66.7–76.8%) out of 308 patients at 6 months and 68.0% (95% CI: 62.7–73.3%) out of 297 patients at 1 year. Overall, ACR20/50/70 responses at 6 months were 41.2% (80/194), 29.4% (57/194), 17.1% (34/199) and at 1-year were 34.9% (66/189), 26.7% (51/191), 18.4% (36/196), respectively. Secondary outcome measures improved rapidly already at 6 months: mean (SD) PASI, available for 87 patients, decreased from 3.2 (5.1) to 0.6 (1.3), the proportion of patients with dactylitis from 23.6% (35/148) to 3.5% (5/142) and those with enthesitis from 33.3% (49/147) to 9.0% (12/133). Conclusions The CHRONOS study provides real-world evidence of the effectiveness of biologics in PsA in the Italian rheumatological practice, confirming the efficacy reported in RCTs across various outcome measures.

Published
2022
Full Text
View/download PDF

45. In inflammatory myopathies, dropped head/bent spine syndrome is associated with scleromyositis: an international case–control study

Author

Jérémie Sellam, Laurent Arnaud, Marta Mosca, Florenzo Iannone, Luca Diamanti, Luca Iaccarino, Aurélien Guffroy, Jacques-Eric Gottenberg, Veronica Codullo, Alain Meyer, Simone Barsotti, Jelena Blagojevic, Lorenzo Cavagna, François Séverac, Bernard Geny, Jean Sibilia, Marie Hudson, François Maurier, Benjamin Terrier, Silvia Bellando-Randone, Emanuelle Dernis, Carlotta Nannini, Marion Couderc, Anne Tournadre, Jean Jacques Dubost, Albert Selva-O'Callaghan, Claire de Moreuil, Giacomo Emmi, Baptiste Hervier, Guilhem Sole, Philippe Guilpain, Jean-François Viallard, Aleksandra Nadaj-Pakleza, Enrico Marchioni, Monica Groza, Sergio Prieto-González, Nicolas Poursac, Isabelle Guichard, Kubéraka Mariampillai, Yves Troyanov, Luc Pijnenburg, Antoine Soulages, Jean-Marc Galempoix, Margherita Giannini, Maude Bouchard-Marmen, Livio Bernardi, Paola Bini, Fanny Duval, Delphine Lebrun, Jean-Maxime Piot, Eglantine Rouanet, Nathalie Vernier, Veronique Vesperini, and Rahima Ziane

Subjects
Medicine
Abstract

Background Some myopathies can lead to dropped head or bent spine syndrome (DH/BS). The significance of this symptom has not been studied in inflammatory myopathies (IM).Objectives To assess the significance of DH/BS in patients with IM.Methods Practitioners from five IM networks were invited to report patients with IM suffering from DH/BS (without other known cause than IM). IM patients without DH/BS, randomly selected in each participating centre, were included as controls at a ratio of 2 to 1.Results 49 DH/BS-IM patients (DH: 57.1%, BS: 42.9%) were compared with 98 control-IM patients. DH/BS-IM patients were older (65 years vs 53 years, p

Published
2023
Full Text
View/download PDF

46. DLco and echocardiographic parameters in identifying mild pulmonary hypertension in the EUSTAR cohort of systemic sclerosis patients

Author

Colalillo, Amalia, primary, Hachulla, Eric, additional, Pellicano, Chiara, additional, Smith, Vanessa, additional, Bergmann, Christina, additional, Riemekasten, Gabriela, additional, Zanatta, Elisabetta, additional, Henes, Jörg, additional, Launay, David, additional, Marcoccia, Antonella, additional, Gheorghiu, Ana Maria, additional, Truchetet, Marie-Elise, additional, Iannone, Florenzo, additional, Simeón Aznar, Carmen Pilar, additional, Oliveira, Susana, additional, Vonk, Madelon, additional, Del Galdo, Francesco, additional, Rosato, Edoardo, additional, Distler, Oliver, additional, Becker, Mike, additional, De Decker, Melissa, additional, Fegatelli, Danilo Alunni, additional, Siegert, Elise, additional, Castellví, Ivan, additional, Cauli, Alberto, additional, Solanki, Kamal, additional, Dagna, Lorenzo, additional, Martin, Mickaël, additional, Moroncini, Gianluca, additional, Poormoghim, Hadi, additional, Kuwana, Masataka, additional, Carreira, Patricia E., additional, Airò, Paolo, additional, Spierings, Julia, additional, Tanaka, Yoshiya, additional, Selvi, Enrico, additional, and Soukup, Tomas, additional

Published
2024
Full Text
View/download PDF

47. Orofacial Manifestation of Systemic Sclerosis: A Cross-Sectional Study and Future Prospects of Oral Capillaroscopy

Author

Anna Antonacci, Emanuela Praino, Antonia Abbinante, Gianfranco Favia, Cinzia Rotondo, Nicola Bartolomeo, Massimo Giotta, Florenzo Iannone, Germano Orrù, Maria Teresa Agneta, Saverio Capodiferro, Giuseppe Barile, and Massimo Corsalini

Subjects
scleroderma, capillaroscopy, oral health, quality of life, Medicine (General), R5-920
Abstract

Background and objectives: oral alterations in Systemic Sclerosis (SSc) patients are widespread and include microstomia, periodontitis, telangiectasias, mandibular resorption, bone lesions, and xerostomia. This cross-sectional study aims to evaluate the differences between SSc patients (cases) and healthy subjects (controls) regarding oral manifestations, quality of life (QoL), and microcirculation alterations. Methods: plaque index (PCR), periodontal index (PSR), DMFT, salivary flow rate, and buccal opening were measured by expert clinicians. S-HAQ test, the Self-Rating Anxiety State (SAS), the Self-Rating Depression Scale (SDS), and the WHOQOL-BREF test were administered to patients to evaluate their QoL. Microvascular alterations were assessed by oral videocapillaroscopy, performed on gingival and labial mucosa. A statistical analysis was conducted to find significant differences between healthy people and SSc patients. Results: 59 patients were enrolled in this study. Standard salivary flow is significantly more frequent in controls, while xerostomia, reduced flow, microstomia, lip retraction, and periodontitis are significantly more frequent in the cases. Gingival capillaroscopy showed differences concerning loop visibility, thickening of the gum, tortuosity of gingival loops, and reduced gingival density. Labial capillaroscopy demonstrates that visibility of the labial loops, the labial ectasias, and the tortuosity of the loops are significantly associated with the presence of scleroderma. Hand and facial deformities, hypomobility of the tongue, cheeks, lips, microstomia, and xerostomia significantly compromised the quality of life of SSc patients, which was significantly worse among them. Moreover, oral videocapillaroscopy could be a proper diagnostic method to detect oral microcirculation alterations. SSc patients often present ectasias, rarefaction of the reticulum, microhemorrhages, and megacapillaries, which negatively impact their oral health. Conclusions: periodontitis, reduced salivary flow, and microstomia could be considered SSc oral manifestations. Joint deformities, facial appearance, and comorbidities significantly reduce the QoL of SSc patients compared to healthy subjects. Oral videocapillaroscopy could be an innovative and reliable technique to detect oral microcirculation anomalies.

Published
2024
Full Text
View/download PDF

48. Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases

Author

Ursini, Francesco, Ruscitti, Piero, Raimondo, Vincenzo, De Angelis, Rossella, Cacciapaglia, Fabio, Pigatto, Erika, Olivo, Domenico, Di Cola, Ilenia, Galluccio, Felice, Francioso, Francesca, Foti, Rosario, Tavoni, Antonio Gaetano, D’Angelo, Salvatore, Campochiaro, Corrado, Motta, Francesca, De Santis, Maria, Bilia, Silvia, Bruno, Caterina, De Luca, Giacomo, Visentini, Marcella, Ciaffi, Jacopo, Mancarella, Luana, Brusi, Veronica, D’Onghia, Martina, Cuomo, Giovanna, Fusaro, Enrico, Cipriani, Paola, Dagna, Lorenzo, Guiducci, Serena, Meliconi, Riccardo, Iannone, Florenzo, Iagnocco, Annamaria, Giacomelli, Roberto, and Ferri, Clodoveo

Published
2022
Full Text
View/download PDF

50. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Matucci Cerinic, Marco, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Kowal Bielecka, Otylia, Cutolo, Maurizio, Cuomo, Giovanna, Kedor, Claudia, Rednic, Simona, Avouac, Jérome, Vlachoyiannopoulos, P., Montecucco, C., Stork, Jiri, Inanc, Murat, Carreira, Patricia E., Novak, Srdan, Czirják, László, Iudici, Michele, Kucharz, Eugene J., Zanatta, Elisabetta, Perdan-Pirkmajer, Katja, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstrand, Roger, Radic, Mislav, Braun-Moscovici, Yolanda, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Vonk, Madelon, Damjanov, Nemanja, Henes, Jörg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Kohm, Michaela, Foeldvari, Ivan, Bajocchi, Gianluigi, Salvador, Maria João, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Ananieva, Lidia P., Herrick, Ariane, Müller-Ladner, Ulf, De Palma, Raffaele, Engelhart, Merete, Szücs, Gabriela, Sobrino Grande, Cristina, Midtvedt, Øyvind, Launay, David, Riccieri, Valeria, Ionescu, Ruxandra Maria, Sha, Ami, Gheorghiu, Ana Maria, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Ullman, Susanne, Alberto von Mühlen, Carlos, Pozzi, Maria Rosa, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Alegre-Sancho, Juan Jose, Herrmann, Kristine, De Langhe, Ellen, Anic, Branimir, Üprus, Maria, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Busquets, Joanna, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Sampaio-Barros, Percival D., Stamp, Lisa, Solanki, Kamal, Veale, Douglas, Loyo, Esthela, Li, Mengtao, Abdel Atty Mohamed, Walid Ahmed, Gigante, Antonietta, Oksel, Fahrettin, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Abignano, Giuseppina, Seskute, Goda, Saketkoo, Lesley Ann, Kerzberg, Eduardo, Bianchi, Washington, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, François, Marcoccia, Antonella, Kahl, Sarah, Hsu, Ivien M., Martin, Thierry, Moiseev, Sergey, Chung, Lorinda S., Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Sommerlatte, Sabine, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Francis, Belloli, Laura, Sfikakis, Petros, Markus, Juliana, Feldman, Gary R, Ramazan, Ana-Maria, Scherer, H.U., Truchetet, Marie-Elise, Lescoat, Alain, Dagna, Lorenzo, van Laar, J.M., Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, Martin, Mickaël, Tanaka, Yoshiya, Elhai, Muriel, Sritharan, Nanthara, Boubaya, Marouane, Balbir-Gurman, Alexandra, Siegert, Elise, Hachulla, Eric, de Vries-Bouwstra, Jeska, Riemekasten, Gabriela, Distler, Jörg H W, Rosato, Edoardo, Del Galdo, Francesco, Mendoza, Fabian A, Furst, Daniel E, de la Puente, Carlos, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Bloch-Queyrat, Coralie, and Allanore, Yannick

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results